Current gene therapy using viral vectors for chronic pain

Molecular Pain

Volumn 11, Issue 1, 2015, Pages

  Guedon, Jean Marc G ^a   Wu, Shaogen ^b   Zheng, Xuexing ^c   Churchill, Caroline C ^d   Glorioso, Joseph C ^a   Liu, Ching Hang ^c   Liu, Shue ^c   Vulchanova, Lucy ^d   Bekker, Alex ^b   Tao, Yuan Xiang ^b,e   Kinchington, Paul R ^a   Goins, William F ^a   Fairbanks, Carolyn A ^d   Hao, Shuanglin ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Gene therapy; Pain; Viral vectors

Indexed keywords

AMITRIPTYLINE; COMPLEMENTARY RNA; CYTOKINE; DICLOFENAC; ENKEPHALIN; HERPES SIMPLEX VIRUS 1 VECTOR; HERPES SIMPLEX VIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 4; MORPHINE; MYELOID ZINC FINGER PROTEIN 1; NARCOTIC ANALGESIC AGENT; PARVOVIRUS VECTOR; POTASSIUM CHANNEL KV1.2; PREPROENKEPHALIN; RECOMBINANT INTERLEUKIN 10; RNA; SENSE RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; ANALGESIC AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER PAIN; CHRONIC PAIN; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DRUG WITHDRAWAL; GENE EXPRESSION REGULATION; HERPES ZOSTER; HUMAN; HYPERALGESIA; INTERSTITIAL CYSTITIS; NEUROCHEMISTRY; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NERVE INJURY; PHASE 1 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSORY NERVE CELL; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL TROPISM; ANALGESIA; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; PROCEDURES;

ANALGESICS; ANIMALS; CHRONIC PAIN; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PAIN MANAGEMENT; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 84930206269     PISSN: 17448069     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/s12990-015-0018-1     Document Type: Article

References (206)

1. IOM. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington DC: National Academies Press(US); 2011.
2. Wolfe D, Mata M, Fink DJ. Targeted drug delivery to the peripheral nervous system using gene therapy. Neurosci Lett. 2012;527:85-9.
3. Hao S, Mata M, Fink DJ. Viral vector-based gene transfer for treatment of chronic pain. Int Anesthesiol Clin. 2007;45:59-71.
4. Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis. 2012;48:179-88.
5. Braz J, Beaufour C, Coutaux A, Epstein AL, Cesselin F, Hamon M, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001;21:7881-8.
6. Lu Y, McNearney TA, Lin W, Wilson SP, Yeomans DC, Westlund KN. Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol Ther. 2007;15:1812-9.
7. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003;102:135-42.
8. Meunier A, Latremoliere A, Mauborgne A, Bourgoin S, Kayser V, Cesselin F, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther. 2005;11:608-16.
9. Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, Hu X, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol. 2002;52:662-5.
10. Fink DJ, Wechuck J, Mata M, Glorioso JC, Goss J, Krisky D, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70:207-12.
11. Chattopadhyay M, Mata M, Fink DJ. Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. Eur J Pain. 2011;15:913-20.
12. Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain. 2006;2:6.
13. Zhou Z, Peng X, Hao S, Fink DJ, Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther. 2008;15:183-90.
14. Yeomans DC, Levinson SR, Peters MC, Koszowski AG, Tzabazis AZ, Gilly WF, et al. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther. 2005;16:271-7.
15. Wolfe D, Mata M, Fink DJ. A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther. 2009;16:455-60.
16. Ruzo A, Marco S, Garcia M, Villacampa P, Ribera A, Ayuso E, et al. Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther. 2012;23:1237-46.
17. Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014;10:571-81.
18. Marks Jr WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:1164-72.
19. Ramaswamy S, Kordower JH. Gene therapy for Huntington's disease. Neurobiol Dis. 2012;48:243-54.
20. Weinberg MS, Samulski RJ, McCown TJ. Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology. 2013;69:82-8.
21. Dirren E, Towne CL, Setola V, Redmond Jr DE, Schneider BL, Aebischer P. Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord. Hum Gene Ther. 2014;25:109-20.
22. Beutler AS, Reinhardt M. AAV for pain: steps towards clinical translation. Gene Ther. 2009;16:461-9.
23. Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther. 2002;9:1387-95.
24. Samad OA, Tan AM, Cheng X, Foster E, Dib-Hajj SD, Waxman SG. Virus-mediated shRNA knockdown of Na(v)1.3 in rat dorsal root ganglion attenuates nerve injury-induced neuropathic pain. Mol Ther. 2013;21:49-56.
25. Storek B, Reinhardt M, Wang C, Janssen WG, Harder NM, Banck MS, et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci U S A. 2008;105:1055-60.
26. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2012;23:382-9.
27. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20:450-9.
28. Vulchanova L, Schuster DJ, Belur LR, Riedl MS, Podetz-Pedersen KM, Kitto KF, et al. Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol Pain. 2010;6:31.
29. Towne C, Pertin M, Beggah AT, Aebischer P, Decosterd I. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol Pain. 2009;5:52.
30. Pleticha J, Malkmus SA, Heilmann LF, Veesart SL, Rezek R, Xu Q, et al. High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs. Gene Ther. 2015;22:202-8.
31. Schuster DJ, Belur LR, Riedl MS, Schnell SA, Podetz-Pedersen KM, Kitto KF, et al. Supraspinal gene transfer by intrathecal adeno-associated virus serotype 5. Front Neuroanat. 2014;8:66.
32. Schuster DJ, Dykstra JA, Riedl MS, Kitto KF, Belur LR, McIvor RS, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 2014;8:42.
33. Yaksh TL, Collins JG. Studies in animals should precede human use of spinally administered drugs. Anesthesiology. 1989;70:4-6.
34. Bernards CM. Epidural and Intrathecal drug movement. In: Yaksh TL, editor. Spinal drug delivery. 1999. p. 239-52.
35. Yaksh TL, Hobo S, Peters C, Osborn KG, Richter Jr PJ, Rossi SS, et al. Preclinical toxicity screening of intrathecal oxytocin in rats and dogs. Anesthesiology. 2014;120:951-61.
36. Samaranch L, San Sebastian W, Kells AP, Salegio EA, Heller G, Bringas JR, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther. 2014;22:329-37.
37. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654-62.
38. Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16:191-8.
39. Yawn BP, Wollan PC, Weingarten TN, Watson JC, Hooten WM, Melton 3rd LJ. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10:586-93.
40. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77-92.
41. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1-32.
42. Devor M. The pathophysiology of damaged peripheral nerve. In: Texbook of pain. 3rd ed. London: Churchill Livingston; 1994. p. 79-100.
43. Lutz BM, Bekker A, Tao YX. Noncoding RNAs: new players in chronic pain. Anesthesiology. 2014;121:409-17.
44. Wang W, Gu J, Li YQ, Tao YX. Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain? Mol Pain. 2011;7:16.
45. Zhao X, Tang Z, Zhang H, Atianjoh FE, Zhao JY, Liang L, et al. A long noncoding RNA contributes to neuropathic pain by silencing Kcna2 in primary afferent neurons. Nat Neurosci. 2013;16:1024-31.
46. Fan L, Guan X, Wang W, Zhao JY, Zhang H, Tiwari V, et al. Impaired neuropathic pain and preserved acute pain in rats overexpressing voltage-gated potassium channel subunit Kv1.2 in primary afferent neurons. Mol Pain. 2014;10:8.
47. Chien LY, Cheng JK, Chu D, Cheng CF, Tsaur ML. Reduced expression of A-type potassium channels in primary sensory neurons induces mechanical hypersensitivity. J Neurosci. 2007;27:9855-65.
48. Targ EF, Kocsis JD. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res. 1986;363:1-9.
49. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res. 1985;328:358-61.
50. Devor M, Govrin-Lippmann R. Axoplasmic transport block reduces ectopic impulse generation in injured peripheral nerves. Pain. 1983;16:73-85.
51. Devor M. Potassium channels moderate ectopic excitability of nerve-end neuromas in rats. Neurosci Lett. 1983;40:181-6.
52. Chabal C, Jacobson L, Russell LC, Burchiel KJ. Pain responses to perineuromal injection of normal saline, gallamine, and lidocaine in humans. Pain. 1989;36:321-5.
53. Ocaña M, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol. 2004;500:203-19.
54. Rasband MN, Park EW, Vanderah TW, Lai J, Porreca F, Trimmer JS. Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci U S A. 2001;98:13373-8.
55. Park SY, Choi JY, Kim RU, Lee YS, Cho HJ, Kim DS. Downregulation of voltage-gated potassium channel alpha gene expression by axotomy and neurotrophins in rat dorsal root ganglia. Mol Cells. 2003;16:256-9.
56. Kim DS, Choi JO, Rim HD, Cho HJ. Downregulation of voltage-gated potassium channel alpha gene expression in dorsal root ganglia following chronic constriction injury of the rat sciatic nerve. Brain Res Mol Brain Res. 2002;105:146-52.
57. Kim DS, Lee SJ, Cho HJ. Differential usage of multiple brain-derived neurotrophic factor promoter in rat dorsal root ganglia following peripheral nerve injuries and inflammation. Brain Res Mol Brain Res. 2001;92:167-71.
58. Ishikawa K, Tanaka M, Black JA, Waxman SG. Changes in expression of voltage-gated potassium channels in dorsal root ganglion neurons following axotomy. Muscle Nerve. 1999;22:502-7.
59. Everill B, Kocsis JD. Nerve growth factor maintains potassium conductance after nerve injury in adult cutaneous afferent dorsal root ganglion neurons. Neuroscience. 2000;100:417-22.
60. Yang EK, Takimoto K, Hayashi Y, de Groat WC, Yoshimura N. Altered expression of potassium channel subunit mRNA and alpha-dendrotoxin sensitivity of potassium currents in rat dorsal root ganglion neurons after axotomy. Neuroscience. 2004;123:867-74.
61. Tal M, Wall PD, Devor M. Myelinated afferent fiber types that become spontaneously active and mechanosensitive following nerve transection in the rat. Brain Res. 1999;824:218-23.
62. Liu CN, Wall PD, Ben-Dor E, Michaelis M, Amir R, Devor M. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. Pain. 2000;85:503-21.
63. Liu CN, Michaelis M, Amir R, Devor M. Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: relation to neuropathic pain. J Neurophysiol. 2000;84:205-15.
64. Luo X, Zhang X, Shao W, Yin Y, Zhou J. Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures. J Neurochem. 2009;108:952-61.
65. Hsieh YH, Wu TT, Tsai JH, Huang CY, Hsieh YS, Liu JY. PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem Biophys Res Commun. 2006;339:217-25.
66. Massengill JS, Kittredge JL. Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider. J Pain Res. 2014;7:125-32.
67. Opstelten W, McElhaney J, Weinberger B, Oaklander AL, Johnson RW. The impact of varicella zoster virus: chronic pain. J Clin Virol. 2010;48 Suppl 1:S8-13.
68. Karbassi M, Raizman MB, Schuman JS. Herpes zoster ophthalmicus. Surv Ophthalmol. 1992;36:395-410.
69. Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol. 2010;48 Suppl 1:S20-8.
70. Galluzzi KE. Management strategies for herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc. 2007;107:S8-13.
71. Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine. 1998;16:1768-70.
72. Yawn BP, Wollan PC, St Sauver JL, Butterfield LC. Herpes zoster eye complications: rates and trends. Mayo Clin Proc. 2013;88:562-70.
73. Philip A, Thakur R. Post herpetic neuralgia. J Palliat Med. 2011;14:765-73.
74. Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport. 1996;7:2897-901.
75. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience. 1996;73:625-9.
76. Zelenka M, Schafers M, Sommer C. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain. 2005;116:257-63.
77. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res. 1999;829:209-21.
78. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res. 1996;16:695-700.
79. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521-32.
80. Failla V, Jacques J, Castronovo C, Nikkels AF. Herpes zoster in patients treated with biologicals. Dermatology. 2012;224:251-6.
81. Russell FA, Fernandes ES, Courade JP, Keeble JE, Brain SD. Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling. Pain. 2009;142:264-74.
82. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737-44.
83. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev. 2007;56:148-69.
84. Li W, Shi X, Wang L, Guo T, Wei T, Cheng K, et al. Epidermal adrenergic signaling contributes to inflammation and pain sensitization in a rat model of complex regional pain syndrome. Pain. 2013;154:1224-36.
85. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010;229:26-50.
86. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol. 2005;192:444-62.
87. Zhang Q, Wang J, Duan MT, Han SP, Zeng XY, Wang JY. NF-kappaB, ERK, p38 MAPK and JNK contribute to the initiation and/or maintenance of mechanical allodynia induced by tumor necrosis factor-alpha in the red nucleus. Brain Res Bull. 2013;99:132-9.
88. Zeng XY, Zhang Q, Wang J, Yu J, Han SP, Wang JY. Distinct role of tumor necrosis factor receptor subtypes 1 and 2 in the red nucleus in the development of neuropathic pain. Neurosci Lett. 2014;569:43-8.
89. Gao YJ, Zhang L, Ji RR. Spinal injection of TNF-alpha-activated astrocytes produces persistent pain symptom mechanical allodynia by releasing monocyte chemoattractant protein-1. Glia. 2010;58:1871-80.
90. Ogawa N, Kawai H, Terashima T, Kojima H, Oka K, Chan L, et al. Gene therapy for neuropathic pain by silencing of TNF-alpha expression with lentiviral vectors targeting the dorsal root ganglion in mice. PLoS One. 2014;9, e92073.
91. Ohtori S, Takahashi K, Moriya H, Myers RR. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine (Phila Pa 1976). 2004;29:1082-8.
92. Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience. 1997;81:255-62.
93. Schafers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci. 2003;23:3028-38.
94. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361:184-7.
95. Drory VE, Lev D, Groozman GB, Gutmann M, Klausner JM. Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci. 1998;158:1-4.
96. Murata Y, Onda A, Rydevik B, Takahashi I, Takahashi K, Olmarker K. Changes in pain behavior and histologic changes caused by application of tumor necrosis factor-alpha to the dorsal root ganglion in rats. Spine (Phila Pa 1976). 2006;31:530-5.
97. Youn DH, Wang H, Jeong SJ. Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J Neurosci Res. 2008;86:2867-75.
98. Mata M, Hao S, Fink DJ. Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha. Neurosci Lett. 2008;437:209-13.
99. Zhou Z, Peng X, Hagshenas J, Insolera R, Fink DJ, Mata M. A novel cell-cell signaling by microglial transmembrane TNFalpha with implications for neuropathic pain. Pain. 2010;151:296-306.
100. Fleetwood-Walker SM, Quinn JP, Wallace C, Blackburn-Munro G, Kelly BG, Fiskerstrand CE, et al. Behavioural changes in the rat following infection with varicella-zoster virus. J Gen Virol. 1999;80(Pt 9):2433-6.
101. Kinchington PR, Goins WF. Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. J Neurovirol. 2011;17:590-9.
102. Delaney A, Colvin LA, Fallon MT, Dalziel RG, Mitchell R, Fleetwood-Walker SM. Postherpetic neuralgia: from preclinical models to the clinic. Neurotherapeutics. 2009;6:630-7.
103. Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin WJ, et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain. 2005;118:97-111.
104. Guedon JM, Zhang M, Glorioso JC, Goins WF, Kinchington PR. Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin. Gene Ther. 2014;21(7):694-702.
105. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience. 2007;144:1495-508.
106. Dalziel RG, Bingham S, Sutton D, Grant D, Champion JM, Dennis SA, et al. Allodynia in rats infected with varicella zoster virus-a small animal model for post-herpetic neuralgia. Brain Res Brain Res Rev. 2004;46:234-42.
107. Blackbeard J, Wallace VC, O'Dea KP, Hasnie F, Segerdahl A, Pheby T, et al. The correlation between pain-related behaviour and spinal microgliosis in four distinct models of peripheral neuropathy. Eur J Pain. 2012;16:1357-67.
108. Medhurst SJ, Collins SD, Billinton A, Bingham S, Dalziel RG, Brass A, et al. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain. 2008;138:61-9.
109. Zhang GH, Lv MM, Wang S, Chen L, Qian NS, Tang Y, et al. Spinal astrocytic activation is involved in a virally-induced rat model of neuropathic pain. PLoS One. 2011;6, e23059.
110. Nurmikko T, Bowsher D. Somatosensory findings in postherpetic neuralgia. J Neurol Neurosurg Psychiatry. 1990;53:135-41.
111. Baron R, Tolle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain. 2009;146:34-40.
112. Rowbotham MC, Yosipovitch G, Connolly MK, Finlay D, Forde G, Fields HL. Cutaneous innervation density in the allodynic form of postherpetic neuralgia. Neurobiol Dis. 1996;3:205-14.
113. Levin MJ, Gershon AA, Dworkin RH, Brisson M, Stanberry L. Prevention strategies for herpes zoster and post-herpetic neuralgia. J Clin Virol. 2010;48 Suppl 1:S14-9.
114. Goins WF, Cohen JB, Glorioso JC. Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol Dis. 2012;48:255-70.
115. Sun J, Liu S, Mata M, Fink DJ, Hao S. Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats. Gene Ther. 2012;19:101-8.
116. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'Connor K, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci. 2005;21:2136-48.
117. Ledeboer A, Mahoney JH, Milligan ED, Martin D, Maier SF, Watkins LR. Spinal cord glia and interleukin-1 do not appear to mediate persistent allodynia induced by intramuscular acidic saline in rats. J Pain. 2006;7:757-67.
118. Funahashi Y, Oguchi T, Goins WF, Gotoh M, Tyagi P, Goss JR, et al. Herpes simplex virus vector mediated gene therapy of tumor necrosis factor-alpha blockade for bladder overactivity and nociception in rats. J Urol. 2013;189:366-73.
119. Meunier A, Latremoliere A, Dominguez E, Mauborgne A, Philippe S, Hamon M, et al. Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther. 2007;15:687-97.
120. Oguchi T, Funahashi Y, Yokoyama H, Nishizawa O, Goins WF, Goss JR, et al. Effect of herpes simplex virus vector-mediated interleukin-4 gene therapy on bladder overactivity and nociception. Gene Ther. 2013;20:194-200.
121. Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007;14:1010-6.
122. Peng XM, Zhou ZG, Glorioso JC, Fink DJ, Mata M. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol. 2006;59:843-51.
123. Jones JO, Arvin AM. Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol. 2003;77:1268-80.
124. Clark AK, Old EA, Malcangio M. Neuropathic pain and cytokines: current perspectives. J Pain Res. 2013;6:803-14.
125. Huang W, Zheng W, Liu S, Zeng W, Levitt RC, Candiotti KA, et al. HSV-mediated p55TNFSR reduces neuropathic pain induced by HIV gp120 in rats through CXCR4 activity. Gene Ther. 2014;21:328-36.
126. Tresch S, Trueb RM, Kamarachev J, French LE, Hofbauer GF. Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. Dermatology. 2009;219:347-9.
127. Di Costanzo L, Ayala F, Megna M, Gaudiello F, Patri A, Balato N. The risk of herpes zoster in the anti-TNF-alpha era: a case report and review of the literature. J Dermatol Case Rep. 2013;7:1-4.
128. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48:1364-71.
129. Dreiher J, Kresch FS, Comaneshter D, Cohen AD. Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26:1127-32.
130. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34.
131. Gentile G, Foa R. Viral infections associated with the clinical use of monoclonal antibodies. Clin Microbiol Infect. 2011;17:1769-75.
132. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159:1217-28.
133. Leung L, Cahill CM. TNF-alpha and neuropathic pain-a review. J Neuroinflammation. 2010;7:27.
134. Portenoy RK, Ugarte C, Fuller I, Haas G. Population-based survey of pain in the United States: differences among white, African American, and Hispanic subjects. J Pain. 2004;5:317-28.
135. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain. 2010;11:1230-9.
136. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
137. DuPen A, Shen D, Ersek M. Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs. 2007;8:113-21.
138. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci. 2002;22:9980-9.
139. Muscoli C, Cuzzocrea S, Ndengele MM, Mollace V, Porreca F, Fabrizi F, et al. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J Clin Invest. 2007;117:3530-9.
140. Ndengele MM, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, et al. Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther. 2009;329:64-75.
141. Glorioso JC, Mata M, Fink DJ. Therapeutic gene transfer to the nervous system using viral vectors. J Neurovirol. 2003;9:165-72.
142. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10:309-19.
143. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol. 2004;58:253-71.
144. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267-84.
145. Yaksh TL, Hua XY, Kalcheva I, Nozaki-Taguchi N, Marsala M. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci U S A. 1999;96:7680-6.
146. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci. 2002;22:6724-31.
147. Hwang JH, Yaksh TL. The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain. 1997;70:15-22.
148. Malan TP, Mata HP, Porreca F. Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology. 2002;96:1161-7.
149. Sivilotti L, Woolf CJ. The contribution of GABAA and glycine receptors to central sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol. 1994;72:169-79.
150. LaMotte CC, Kapadia SE. Deafferentation-induced terminal field expansion of myelinated saphenous afferents in the adult rat dorsal horn and the nucleus gracilis following pronase injection of the sciatic nerve. J Comp Neurol. 1993;330:83-94.
151. Mannion RJ, Doubell TP, Coggeshall RE, Woolf CJ. Collateral sprouting of uninjured primary afferent A-fibers into the superficial dorsal horn of the adult rat spinal cord after topical capsaicin treatment to the sciatic nerve. J Neurosci. 1996;16:5189-95.
152. Baba H, Doubell TP, Woolf CJ. Peripheral inflammation facilitates Abeta fiber-mediated synaptic input to the substantia gelatinosa of the adult rat spinal cord. J Neurosci. 1999;19:859-67.
153. Baba H, Ji RR, Kohno T, Moore KA, Ataka T, Wakai A, et al. Removal of GABAergic inhibition facilitates polysynaptic A fiber-mediated excitatory transmission to the superficial spinal dorsal horn. Mol Cell Neurosci. 2003;24:818-30.
154. Colton C, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets. 2010;9:174-91.
155. Smith HS. Activated microglia in nociception. Pain Physician. 2010;13:295-304.
156. De Leo JA, Tawfik VL, LaCroix-Fralish ML. The tetrapartite synapse: path to CNS sensitization and chronic pain. Pain. 2006;122:17-21.
157. Guo W, Wang H, Watanabe M, Shimizu K, Zou S, LaGraize SC, et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007;27:6006-18.
158. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol. 1997;121:417-24.
159. LaMotte CC, Kapadia SE, Arsenault K, Wolfe M. Deafferentation-induced expression of GAP-43, NCAM, and NILE in the adult rat dorsal horn following pronase injection of the sciatic nerve. Somatosens Mot Res. 1995;12:71-9.
160. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, et al. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg. 2011;112:454-9.
161. Merighi S, Gessi S, Varani K, Fazzi D, Stefanelli A, Borea PA. Morphine mediates a proinflammatory phenotype via mu-opioid receptor-PKCvarepsilon-Akt-ERK1/2 signaling pathway in activated microglial cells. Biochem Pharmacol. 2013;86:487-96.
162. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. 2005;28:661-9.
163. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 1995;62:259-74.
164. Mayer DJ, Mao J, Holt J, Price DD. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci U S A. 1999;96:7731-6.
165. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol. 1998;151:138-42.
166. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23:2517-21.
167. Hao S, Wolfe D, Glorioso JC, Mata M, Fink DJ. Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur J Pain. 2009;13:380-6.
168. Maeda S, Kawamoto A, Yatani Y, Shirakawa H, Nakagawa T, Kaneko S. Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats. Mol Pain. 2008;4:65.
169. Lee B, Kim J, Kim SJ, Lee H, Chang JW. Constitutive GABA expression via a recombinant adeno-associated virus consistently attenuates neuropathic pain. Biochem Biophys Res Commun. 2007;357:971-6.
170. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol. 2005;57:914-8.
171. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ. HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther. 2003;8:367-75.
172. Newcomb WW, Homa FL, Thomsen DR, Trus BL, Cheng N, Steven A, et al. Assembly of the herpes simplex virus procapsid from purified components and identification of small complexes containing the major capsid and scaffolding proteins. J Virol. 1999;73:4239-50.
173. Campbell ME, Palfreyman JW, Preston CM. Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol. 1984;180:1-19.
174. Preston CM, Frame MC, Campbell ME. A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell. 1988;52:425-34.
175. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A. 1999;96:3211-6.
176. Yeomans DC, Wilson SP. Herpes virus-based recombinant herpes vectors: gene therapy for pain and molecular tool for pain science. Gene Ther. 2009;16:502-8.
177. Fink DJ, DeLuca NA, Goins WF, Glorioso JC. Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci. 1996;19:265-87.
178. Yeomans DC, Jones T, Laurito CE, Lu Y, Wilson SP. Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin. Mol Ther. 2004;9:24-9.
179. Gautam S, Tebo JM, Hamilton TA. IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages. J Immunol. 1992;148:1725-30.
180. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991;77:1859-70.
181. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
182. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain. 1998;74:35-42.
183. Milligan ED, Sloane EM, Langer SJ, Hughes TS, Jekich BM, Frank MG, et al. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain. 2006;126:294-308.
184. Milligan ED, Soderquist RG, Malone SM, Mahoney JH, Hughes TS, Langer SJ, et al. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol. 2006;2:293-308.
185. Pohl M, Braz J. Gene therapy of pain: emerging strategies and future directions. Eur J Pharmacol. 2001;429:39-48.
186. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45:555-64.
187. Pacak CA, Byrne BJ. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol Ther. 2011;19:1582-90.
188. Manfredsson FP, Mandel RJ. Development of gene therapy for neurological disorders. Discov Med. 2010;9:204-11.
189. Milligan ED, Sloane EM, Langer SJ, Cruz PE, Chacur M, Spataro L, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.
190. He Z, Guo Q, Xiao M, He C, Zou W. Intrathecal lentivirus-mediated transfer of interleukin-10 attenuates chronic constriction injury-induced neuropathic pain through modulation of spinal high-mobility group box 1 in rats. Pain Physician. 2013;16:E615-25.
191. Lau D, Harte SE, Morrow TJ, Wang S, Mata M, Fink DJ. Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury. Neurorehabil Neural Repair. 2012;26:889-97.
192. Hao S. The molecular and pharmacological mechanisms of HIV-related neuropathic pain. Curr Neuropharmacol. 2013;11:499-512.
193. Zheng W, Huang W, Liu S, Levitt RC, Candiotti KA, Lubarsky DA, et al. Interleukin 10 mediated by herpes simplex virus vectors suppresses neuropathic pain induced by human immunodeficiency virus gp120 in rats. Anesth Analg. 2014;119:693-701.
194. Zheng W, Huang W, Liu S, Levitt RC, Candiotti KA, Lubarsky DA, et al. IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in rats. Mol Pain. 2014;10:49.
195. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC. Cell death in models of spinal cord injury. Prog Brain Res. 2002;137:37-47.
196. Ortmann KL, Chattopadhyay M. Decrease in neuroimmune activation by HSV-mediated gene transfer of TNFalpha soluble receptor alleviates pain in rats with diabetic neuropathy. Brain Behav Immun. 2014;41:144-51.
197. Huang W, Zheng W, Ouyang H, Yi H, Liu S, Zeng W, et al. Mechanical allodynia induced by nucleoside reverse transcriptase inhibitor is suppressed by p55TNFSR mediated by herpes simplex virus vector through the SDF1alpha/CXCR4 system in rats. Anesth Analg. 2014;118:671-80.
198. Hutchinson MR, Watkins LR. Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology. 2014;76 Pt B:218-27.
199. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res. 2001;39:281-6.
200. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004;24:7353-65.
201. Muscoli C, Doyle T, Dagostino C, Bryant L, Chen Z, Watkins LR, et al. Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci. 2010;30:15400-8.
202. Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR. Microglia: a promising target for treating neuropathic and postoperative pain, and morphine tolerance. J Formos Med Assoc. 2011;110:487-94.
203. Tai YH, Tsai RY, Lin SL, Yeh CC, Wang JJ, Tao PL, et al. Amitriptyline suppresses neuroinflammation-dependent interleukin-10-p38 mitogen-activated protein kinase-heme oxygenase-1 signaling pathway in chronic morphine-infused rats. Anesthesiology. 2009;110:1379-89.
204. Wang Z, Chabot JG, Quirion R. On the possible role of ERK, p38 and CaMKII in the regulation of CGRP expression in morphine-tolerant rats. Mol Pain. 2011;7:68.
205. Hutchinson MR, Lewis SS, Coats BD, Skyba DA, Crysdale NY, Berkelhammer DL, et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun. 2009;23:240-50.
206. Hao S, Liu S, Zheng X, Zheng W, Ouyang H, Mata M, et al. The role of TNFalpha in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology. 2011;36:664-76.